


Amendments to the Claims:


This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) Antiatherosclerotic agents agent represented by Formulas I or II:




I



II

wherein

R is



wherein R₉, R₁₀, R₁₁, R₁₂, R₁₃, and R₁₄ are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R_6 , and R_7 are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH_2COOR_8 , where R_8 is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

R_1 is hydrogen or a lower alkyl of 1-6 carbon atoms;


R_2 , R_3 , and R_4 are each, independently, hydrogen or halogen; and

R_5 is a lower alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) The antiatherosclerotic agent of claim 1, wherein:

R is



wherein:

R_9 , R_{10} , R_{11} , R_{12} , R_{13} , and R_{14} are each, independently, hydrogen or lower alkyl of 1 to 6 carbon atoms;

R_6 and R_7 are, each independently, lower alkyl of 1 to 6 carbon atoms; and

X is O or S;

R_1 is hydrogen;

R_2 , R_3 , and R_4 are each, independently, hydrogen or halogen; and

R_5 is a lower alkyl of 1 to 6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)


14. (Withdrawn) The compound of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(3-methyl-isothiazol-5-yl)-thiourea.

15. (Canceled)


16. (Canceled)

17. (Canceled)

18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)
22. (Canceled)
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Canceled)
28. (Currently Amended) A pharmaceutical composition, which comprises an antiatherosclerotic agent represented by Formula I or II:




I



II

wherein

R is



wherein R₉, R₁₀, R₁₁, R₁₂, R₁₃, and R₁₄ are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R₆, and R₇ are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH₂COOR₈, where R₈ is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

R₁ is hydrogen or a lower alkyl of 1-6 carbon atoms;

R₂, R₃, and R₄ are each, independently, hydrogen or halogen; and


R₅ is a lower alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof in association or combination with a pharmaceutically acceptable carrier.

R₅ is a lower alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt thereof.

30. (New) The compound of claim 29, wherein:

R is



wherein:

R₉, R₁₀, R₁₁, R₁₂, R₁₃, and R₁₄ are each, independently, hydrogen or lower alkyl of 1 to 6 carbon atoms;

R₆ and R₇ are, each independently, lower alkyl of 1 to 6 carbon atoms; and

X is O or S;

R₁ is hydrogen;


R₂, R₃, and R₄ are each, independently, hydrogen or halogen; and

R₅ is a lower alkyl of 1 to 6 carbon atoms;


or a pharmaceutically acceptable salt thereof.

31. (New) The compound of claim 29, which is 1-(5-chloro-2-methyl-phenyl)-3-(3-methyl-isothiazol-5-yl)-thiourea.

32. (New) A pharmaceutical composition, which comprises a compound represented by Formula I or II:




I



II

wherein

R is



wherein R_9 , R_{10} , R_{11} , R_{12} , R_{13} , and R_{14} are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

R_6 , and R_7 are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH_2COOR_8 , where R_8 is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

R_1 is hydrogen or a lower alkyl of 1-6 carbon atoms;

R_2 , R_3 , and R_4 are each, independently, hydrogen or halogen; and

R_5 is a lower alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof in association or combination with a pharmaceutically acceptable carrier.